Aafia Chaudhry

945 total citations
49 papers, 542 citations indexed

About

Aafia Chaudhry is a scholar working on Oncology, Pathology and Forensic Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Aafia Chaudhry has authored 49 papers receiving a total of 542 indexed citations (citations by other indexed papers that have themselves been cited), including 32 papers in Oncology, 26 papers in Pathology and Forensic Medicine and 15 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Aafia Chaudhry's work include CAR-T cell therapy research (29 papers), Lymphoma Diagnosis and Treatment (26 papers) and Monoclonal and Polyclonal Antibodies Research (11 papers). Aafia Chaudhry is often cited by papers focused on CAR-T cell therapy research (29 papers), Lymphoma Diagnosis and Treatment (26 papers) and Monoclonal and Polyclonal Antibodies Research (11 papers). Aafia Chaudhry collaborates with scholars based in United States, Spain and South Korea. Aafia Chaudhry's co-authors include Eilon D. Kirson, Uri Weinberg, Yoram Palti, Zéev Bomzon, Noa Urman, Shay Cahal, Moshe Giladi, Roni Blat, Mijal Munster and Aviran Itzhaki and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Aafia Chaudhry

39 papers receiving 527 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Aafia Chaudhry United States 9 238 186 148 141 118 49 542
Almuth F. Keßler Germany 16 209 0.9× 275 1.5× 35 0.2× 88 0.6× 129 1.1× 57 704
Eduard B. Dinca United Kingdom 11 111 0.5× 284 1.5× 79 0.5× 109 0.8× 46 0.4× 17 658
Cathy Brewer United States 10 84 0.4× 367 2.0× 50 0.3× 122 0.9× 75 0.6× 16 547
Timothy H. Ung United States 12 88 0.4× 328 1.8× 25 0.2× 121 0.9× 132 1.1× 40 732
Bertrand Actor Switzerland 9 95 0.4× 282 1.5× 74 0.5× 49 0.3× 56 0.5× 9 575
Jennifer M. Eschbacher United States 12 55 0.2× 155 0.8× 50 0.3× 127 0.9× 78 0.7× 18 432
Stevie Threatt United States 12 140 0.6× 501 2.7× 36 0.2× 84 0.6× 60 0.5× 37 664
Guangrong Lu United States 10 91 0.4× 195 1.0× 21 0.1× 95 0.7× 37 0.3× 21 487
Laëtitia Andrique France 13 160 0.7× 90 0.5× 95 0.6× 103 0.7× 26 0.2× 22 560
Joji Ishida Japan 14 81 0.3× 196 1.1× 31 0.2× 53 0.4× 35 0.3× 49 551

Countries citing papers authored by Aafia Chaudhry

Since Specialization
Citations

This map shows the geographic impact of Aafia Chaudhry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Aafia Chaudhry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Aafia Chaudhry more than expected).

Fields of papers citing papers by Aafia Chaudhry

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Aafia Chaudhry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Aafia Chaudhry. The network helps show where Aafia Chaudhry may publish in the future.

Co-authorship network of co-authors of Aafia Chaudhry

This figure shows the co-authorship network connecting the top 25 collaborators of Aafia Chaudhry. A scholar is included among the top collaborators of Aafia Chaudhry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Aafia Chaudhry. Aafia Chaudhry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Arnason, Jon, Matthew J. Matasar, Stefano Luminari, et al.. (2025). Early clearance of circulating tumor DNA and association with odronextamab response in relapsed/refractory FL and DLBCL. Blood Advances. 9(23). 6130–6140.
2.
Keudell, Gottfried von, Eliza A. Hawkes, Cecilia Carpio, et al.. (2024). Treatment Duration and Risk of Fatal Infections in Patients with B-Cell Non-Hodgkin Lymphoma Achieving Complete Response with Odronextamab. Blood. 144(Supplement 1). 3080–3080.
3.
Vitolo, Umberto, Michele Merli, Lalita Norasetthada, et al.. (2024). Phase 3 trial of odronextamab plus lenalidomide versus rituximab plus lenalidomide in relapsed/refractory (R/R) follicular lymphoma (FL) and marginal zone lymphoma (MZL; OLYMPIA-5).. Journal of Clinical Oncology. 42(16_suppl). TPS7094–TPS7094. 2 indexed citations
4.
Birhiray, Ruemu, Stefano Luminari, Tae Min Kim, et al.. (2024). Phase 3 trial evaluating the efficacy and safety of odronextamab versus investigator’s choice in previously untreated follicular lymphoma (OLYMPIA-1).. Journal of Clinical Oncology. 42(16_suppl). TPS7096–TPS7096. 2 indexed citations
5.
6.
Brouwer‐Visser, Jurriaan, Nathalie Fiaschi, Raquel P. Deering, et al.. (2024). Molecular assessment of intratumoral immune cell subsets and potential mechanisms of resistance to odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory B-cell non-Hodgkin lymphoma. Journal for ImmunoTherapy of Cancer. 12(3). e008338–e008338. 13 indexed citations
7.
Hawkes, Eliza A., Geoffrey Chong, Dina M. Flink, et al.. (2024). Phase 3 trial evaluating the efficacy and safety of odronextamab versus standard-of-care (SOC) therapy in relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL; OLYMPIA-4).. Journal of Clinical Oncology. 42(16_suppl). TPS7093–TPS7093. 2 indexed citations
8.
Gray, Carl, Silvana Novelli, Tuba Hacıbekiroğlu, et al.. (2024). Phase 3 trial evaluating the efficacy and safety of odronextamab plus chemotherapy versus rituximab plus chemotherapy in previously untreated follicular lymphoma (OLYMPIA-2).. Journal of Clinical Oncology. 42(16_suppl). TPS7099–TPS7099. 4 indexed citations
9.
Matasar, Matthew J., Burhan Turgut, Benoît Tessoulin, et al.. (2024). Phase 3 trial evaluating efficacy and safety of odronextamab plus CHOP vs rituximab plus CHOP in previously untreated diffuse large B-cell lymphoma (DLBCL; OLYMPIA-3).. Journal of Clinical Oncology. 42(16_suppl). TPS7086–TPS7086. 6 indexed citations
10.
Allan, John N., Jennifer L. Crombie, Matthew J. Matasar, et al.. (2024). Long-Term Efficacy and Safety of Odronextamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Pooled Analysis from the ELM-1 and ELM-2 Studies. Blood. 144(Supplement 1). 3118–3118. 3 indexed citations
11.
Brém, Elizabeth, Wojciech Jurczak, David Belada, et al.. (2024). Odronextamab Monotherapy in Previously Untreated Patients with High-Risk Follicular Lymphoma (FL): Results of the Safety Lead-in of the Phase 3 Olympia-1 Study. Blood. 144(Supplement 1). 4411–4411. 2 indexed citations
12.
13.
Kim, Tae‐Min, Seok‐Goo Cho, Geoffrey Chong, et al.. (2024). Efficacy and Safety of Odronextamab in Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL): Data from the R/R MZL Cohort in the ELM-2 Study. Blood. 144(Supplement 1). 862–862. 2 indexed citations
14.
15.
16.
Carpio, Cecilia, Nickolas A. Sophos, Min Zhu, et al.. (2023). Trial in Progress: Phase 1 Trial Evaluating the Safety and Tolerability of Odronextamab in Combination with Cemiplimab in Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. Blood. 142(Supplement 1). 3100–3100. 4 indexed citations
17.
Bright, Susan, Srikanth Ambati, Jurriaan Brouwer‐Visser, et al.. (2022). Complete responses to odronextamab in two patients with diffuse large B‐cell lymphoma refractory to chimeric antigen receptor T‐cell therapy. British Journal of Haematology. 199(3). 366–370. 6 indexed citations
18.
Kim, Won-Seog, Tae Min Kim, Seok‐Goo Cho, et al.. (2022). Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2. Blood. 140(Supplement 1). 1070–1071. 24 indexed citations
19.
Connelly, Jennifer, et al.. (2016). Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement. BMC Cancer. 16(1). 842–842. 14 indexed citations
20.
Chaudhry, Aafia, et al.. (2015). NovoTTF™-100A System (Tumor Treating Fields) transducer array layout planning for glioblastoma: a NovoTAL™ system user study. World Journal of Surgical Oncology. 13(1). 316–316. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Almuth F. Keßler Breakdown of academic impact, for papers by Eduard B. Dinca Breakdown of academic impact, for papers by Cathy Brewer Breakdown of academic impact, for papers by Timothy H. Ung Breakdown of academic impact, for papers by Bertrand Actor Breakdown of academic impact, for papers by Jennifer M. Eschbacher Breakdown of academic impact, for papers by Stevie Threatt Breakdown of academic impact, for papers by Guangrong Lu Breakdown of academic impact, for papers by Laëtitia Andrique Breakdown of academic impact, for papers by Joji Ishida
Rankless by CCL
2026